{
    "clinical_study": {
        "@rank": "23265", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "A clinical Study to evaluate the safety and pharmacokinetics/pharmacodynamics(PK/PD) of\n      YH4808 after repeated Oral administration and Postprandial state in healthy volunteers"
        }, 
        "brief_title": "YH4808 Postprandial PK/PD Study in Healthy Subjects", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male and female aged 20 to 55 with a body mass index(BMI) between 18.5 and 25\n             kg/m2\n\n          2. Subject who has no congenital, chronic diseases and disease symptoms in medical\n             examination result\n\n          3. Subject who shows negative reaction of UBT(Urea Breath Test)\n\n          4. Subject who is judged to be eligible by principal investigator or sub-investigator\n             according to various reasons including their abnormal test results (clinical\n             laboratory test, chest X-ray test, 12-lead ECG etc) 4 weeks before the first IP\n             adminitration\n\n          5. Medically acceptable contraception(including individuals who are medically unable to\n             become pregnant) used during the clinical trial\n\n          6. Volunteers who has signed a written informed consent voluntarily, prior to any\n             procedure, using a form that is approved by the local Institutional Review Board\n             after detail explanation of the purpose, contents, and characteristic of the drug\n\n        Exclusion Criteria:\n\n          1. Subject who is hypersensitive to components contained in YH4808 or this drug\n\n          2. Subject who has history or presence of clinically significant diseases in liver,\n             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,\n             blood tumor, cardiovascular, urinary system, and mental disorder\n\n          3. Subject who has history of surgical operation or diseases related to gastrointestinal\n             symtem (e.g. crohn's disaese, ulcer etc except appendectomy or simple for herina)\n\n          4. Other exclusions apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761513", 
            "org_study_id": "YH4808-107"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "description": "Group1\nadminitration of YH4808 dose1, bid for 2weeks\nwash-out period for 3weeks between period1 and period2\nadminitration of YH4808 dose2, qd for 2weeks", 
                "intervention_name": "YH4808", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "description": "Group2\nadminitration of YH4808 dose2, qd for 2weeks\nwash-out period for 3weeks between period1 and period2\nadminitration of YH4808 dose1, bid for 2weeks", 
                "intervention_name": "YH4808", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "description": "Group3\nadminitration of YH4808 dose2, bid for 2weeks\nwash-out period for 3weeks between period1 and period2\nadminitration of Nexium tab 40mg, bid for 2weeks", 
                "intervention_name": "YH4808", 
                "intervention_type": "Drug", 
                "other_name": "YH4808, Nexium"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "description": "Group 4\nadminitration of Nexium tab 40mg, bid for 2weeks\nwash-out period for 3weeks between period1 and period2\nadminitration of YH4808 dose2, bid for 2weeks", 
                "intervention_name": "YH4808", 
                "intervention_type": "Drug", 
                "other_name": "Nexium"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Seodaemun-gu,Sinchon-dong", 
                    "zip": "120-752"
                }, 
                "name": "Yonsei University Health System(Severance Hospital)"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized,Open Label,Active-controlled, Multiple Dosing and Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of YH4808 After Postprandial Oral Administration in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Yonsei University Health System(Severance Hospital)", 
            "last_name": "Minsoo Park, Ph.D, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve of YH4808", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling during 0 ~ 24 hrs after administration"
            }, 
            {
                "measure": "Peak plasma concentration of YH4808", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling during 0~24 hrs after administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761513"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to reach peak plasma concentration of YH4808", 
            "safety_issue": "No", 
            "time_frame": "Blood sampling during 0 ~ 24 hrs after administration"
        }, 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}